Concomitant Radio-chemotherapy in the Elderly (RACCOSA)
Primary Purpose
Non Small Cell Lung Cancer
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Cisplatin IV
Vinorelbine
Radiotherapy
Sponsored by

About this trial
This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring Locally advanced lung cancer, Elderly patients, NSCLC
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 70 years
- Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4), depression score 0-1)
- Performance Status (ECOG) ≤ 1
- Weight loss <10% of usual weight in the last 3 months
- Life expectancy greater than 12 weeks
- Hematologic function: neutrophils> 1.5 x 10**9 / l, hemoglobin> 9.5 g / dl, platelets > 100 x 10**9 / l)
- Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD
- Normal liver function: bilirubin < Limit of Normal (ULN), SGOT and / or SGPT <2.5 x UNL
- Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted
- Patient affiliated to a social security regimen or beneficiary of such regimen
- Informed consent signed
The disease
- Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, undifferentiated carcinoma) histologically or cytologically proven
- Stage IIIAN2 considered inoperable stage IIIB
- Presence of at least one measurable target
- Delay at least three weeks between surgery and initiation of treatment
- No prior treatment with chemotherapy or radiotherapy for lung cancer
Exclusion Criteria:
- Age < 70 years
- Performance Status (ECOG) ≥ 2
- Hematologic function: neutrophils <1.5 x 10**9 / l, hemoglobin <9.5 g / dl, platelets <100 x 10**9 / l)
- Renal function: creatinine clearance <50 ml / min calculated by the formula of MDRD
- Hepatic: bilirubin> Upper Limit of Normal (ULN), SGOT and / or SGPT> 2.5 x ULN
- Respiratory Function: FEV <40% predicted, KCO <60% predicted, PaO2 <60 mmHg
- Peripheral neuropathy grade> 1
- Unstable cardiac pathology requiring treatment (heart failure, angor of effort, arrhythmia) or previous myocardial infarction older than 12 months
- Deafness not paired or deafness requiring major achievement of an audiogram-cons may indicate taking cisplatin
- Neurological or psychiatric disorders prohibiting the understanding of the test
- Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix treated or any other cancer treated with surgery alone or radiotherapy alone extra-thoracic recurrence-free 5 years
- Significant malabsorption syndrome or disease affecting the functioning of the gastrointestinal tract
The disease
- Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small cell carcinoma
- Metastatic disease
- Pleural drain
- Carcinomatous lymphangitis
- Operable Cancer
- Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal therapy, endobronchial suctioning older less than eight days
Sites / Locations
- CHU Brest
- Centre Hospitalier GAP
- Département de Pathologie Respiratoire du CHU de Limoges
- CH de Meaux
- CHU Reims
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
experimental
Arm Description
Outcomes
Primary Outcome Measures
Acute toxicity
Secondary Outcome Measures
Late toxicity
Overall response rate
Full Information
NCT ID
NCT01029678
First Posted
December 9, 2009
Last Updated
May 1, 2018
Sponsor
University Hospital, Limoges
Collaborators
Pierre Fabre Laboratories
1. Study Identification
Unique Protocol Identification Number
NCT01029678
Brief Title
Concomitant Radio-chemotherapy in the Elderly
Acronym
RACCOSA
Official Title
Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Limoges
Collaborators
Pierre Fabre Laboratories
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer
Keywords
Locally advanced lung cancer, Elderly patients, NSCLC
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
experimental
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Cisplatin IV
Intervention Description
Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
Intervention Type
Drug
Intervention Name(s)
Vinorelbine
Intervention Description
Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
Intervention Type
Radiation
Intervention Name(s)
Radiotherapy
Intervention Description
66Gy, 33 fractions, 6 week
Primary Outcome Measure Information:
Title
Acute toxicity
Time Frame
during treatment and during the 4 weeks following the end of treatment
Secondary Outcome Measure Information:
Title
Late toxicity
Time Frame
6 months after the end of the treatment
Title
Overall response rate
Time Frame
4 weeks after treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 70 years
Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4), depression score 0-1)
Performance Status (ECOG) ≤ 1
Weight loss <10% of usual weight in the last 3 months
Life expectancy greater than 12 weeks
Hematologic function: neutrophils> 1.5 x 10**9 / l, hemoglobin> 9.5 g / dl, platelets > 100 x 10**9 / l)
Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD
Normal liver function: bilirubin < Limit of Normal (ULN), SGOT and / or SGPT <2.5 x UNL
Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted
Patient affiliated to a social security regimen or beneficiary of such regimen
Informed consent signed
The disease
Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, undifferentiated carcinoma) histologically or cytologically proven
Stage IIIAN2 considered inoperable stage IIIB
Presence of at least one measurable target
Delay at least three weeks between surgery and initiation of treatment
No prior treatment with chemotherapy or radiotherapy for lung cancer
Exclusion Criteria:
Age < 70 years
Performance Status (ECOG) ≥ 2
Hematologic function: neutrophils <1.5 x 10**9 / l, hemoglobin <9.5 g / dl, platelets <100 x 10**9 / l)
Renal function: creatinine clearance <50 ml / min calculated by the formula of MDRD
Hepatic: bilirubin> Upper Limit of Normal (ULN), SGOT and / or SGPT> 2.5 x ULN
Respiratory Function: FEV <40% predicted, KCO <60% predicted, PaO2 <60 mmHg
Peripheral neuropathy grade> 1
Unstable cardiac pathology requiring treatment (heart failure, angor of effort, arrhythmia) or previous myocardial infarction older than 12 months
Deafness not paired or deafness requiring major achievement of an audiogram-cons may indicate taking cisplatin
Neurological or psychiatric disorders prohibiting the understanding of the test
Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix treated or any other cancer treated with surgery alone or radiotherapy alone extra-thoracic recurrence-free 5 years
Significant malabsorption syndrome or disease affecting the functioning of the gastrointestinal tract
The disease
Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small cell carcinoma
Metastatic disease
Pleural drain
Carcinomatous lymphangitis
Operable Cancer
Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal therapy, endobronchial suctioning older less than eight days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chrystèle LOCHER, MD
Organizational Affiliation
CH Meaux
Official's Role
Study Chair
Facility Information:
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
Centre Hospitalier GAP
City
GAP
Country
France
Facility Name
Département de Pathologie Respiratoire du CHU de Limoges
City
Limoges
Country
France
Facility Name
CH de Meaux
City
Meaux
Country
France
Facility Name
CHU Reims
City
Reims
Country
France
12. IPD Sharing Statement
Learn more about this trial
Concomitant Radio-chemotherapy in the Elderly
We'll reach out to this number within 24 hrs